Nuclear Radiopharmaceutical Market Is Worth $5.55 Billion by 2017

[346 Pages Report] Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017

Logo

Dallas, TX -- (SBWire) -- 11/27/2013 --The Nuclear Medicine Market & Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) – Global Trends & Forecast To 2017 analyzes and studies the major market drivers, restraints, and opportunities in North America, Latin America, Europe, Asia, and Rest of the World.

Browse 142 market data tables with 44 figures spread through 346 pages and in-depth TOC on "Nuclear Medicine Market"
http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

Early buyers will receive 10% customization on this report.
Request for Free PDF Sample @ http://www.marketsandmarkets.com/pdfdownload.asp?id=417

This report studies the global nuclear medicine market over the forecast period 2012-2017.The global radiopharmaceutical market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

The radioisotopes market is categorized into diagnostic and therapeutic applications. The diagnostic market consists of PET and SPECT technologies, while the therapy market comprises of beta emitters and brachytherapy seeds. The SPECT market accounted for a major share of the diagnostic segment in 2012. Significant radioisotopes in the SPECT diagnostic market are Tc-99m, Tl- 201, Ga-67, and I-123, while PET market is dominated by F-18, and Rb-82. The therapy market is led by I-131, Sm-153, Re-186, Y-90, and Lu-177. Alpha emitters are being developed and considered for cancer treatment, however not available commercially.

It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 15% in mature markets of North America, Europe, Japan, the Republic of Korea, and Oceania between 2010 and 2030, however shortage of Mo-99/Tc-99m has been a threat to this industry. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is a major risk for manufacturers in the near future. Companies have increased the production of thallium to meet the shortage, as it is the most commonly used substitute for technetium-99 in cardiac-stress tests, conducted to evaluate the functioning of coronary arteries. Radiopharmaceuticals in neurological applications such as Alzheimer’s disease, Parkinsons disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Two major market strategies were adopted in the global nuclear medicines market by generator manufacturers and radiopharmaceutical processors. In the processors market, shifting of the operational model towards LEU (Low Enriched Uranium) from HEU (High Enriched Uranium) for Mo-99 production was a major trend. Covidien, Nordion, and NTP Radioisotopes Pty. Ltd. were pioneers to establish this adoption. On the other hand, ensuring a sustainable supply chain was the prime aim of generator manufacturers since limited half-life is a major concern in radioisotopes distribution. IBA Group, Lantheus, Covidien, NTP Radioisotopes, and FujiFilm were the key companies to follow this trend.

North America is the dominant market for diagnostic radioisotopes with close to half of the market share. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m.

Processors such as Nordion, Inc., Covidien Plc., and NTP Radioisotopes Pty Ltd. run reactors that are involved in the irradiation of U-235 to make crude isotopes. They follow various strategies to achieve sustainable growth, one of which is shifting to Low Enriched Uranium (LEU) from High Enriched Uranium (HEU). These key players were mainly involved in strategic agreements and contracts with other institutes and players, while generator manufacturers followed several strategies to maintain a sustainable supply chain.

Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany); Cardinal Health dominated with one-fifth of the share in 2012.

Browse Related Reports:
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
http://www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html

European Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Trends & Forecast to 2017
http://www.marketsandmarkets.com/Market-Reports/european-nuclear-medicine-radiopharmaceuticals-market-1107.html

About MarketsandMarkets
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/medical-devices
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

Media Relations Contact

Rohan Salgarkar
MARKETSANDMARKETS
888-391-5441
http://www.marketsandmarkets.com/

View this press release online at: http://rwire.com/395775